Debbie M. Cheng

Debbie M. Cheng

Auto-generated profile, based on publicly available information

Debbie M. Cheng

Department of Biostatistics, School of Public Health, Boston University, Boston, MA, USA

Research Focus & Metrics

Academic Career Length

27Years (2000-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2007 in JAIDS Journal of Acquired Immune Deficiency Syndromes
Verified
Journal Article
Closed access
JSJeffrey Samet
Jeffrey Samet
DCDebbie M ScD Cheng
Debbie M ScD Cheng
HLHoward Libman
Howard Libman
DNDavid P Nunes
David P Nunes
JAJulie K DrPh Alperen
Julie K DrPh Alperen
RSRichard Saitz
Richard Saitz
Objective: To assess the relation between alcohol consumption and laboratory markers of HIV disease progression. Methods: We prospectively assessed CD4 cell counts, HIV RNA levels, and alcohol consumption for up to 7 years in 595 HIV-infected persons with alcohol problems recruited between 1997 and 2003. We investigated the relation of these markers of HIV disease progression to alcohol consumption using longitudinal regression models controlling for known prognostic factors, including adherence and depressive symptoms, and stratified by antiretroviral therapy (ART) use. Results: Among subjects who were not on ART, heavy alcohol consumption was associated with a lower CD4 cell count (adjusted mean decrease of 48.6 cells/μL compared with abstinence; P = 0.03) but not with higher log10 HIV RNA. Among subjects who were on ART, heavy alcohol consumption was not associated with a lower CD4 cell count or higher log10 HIV RNA. Conclusions: Heavy alcohol consumption has a negative impact on the CD4 cell count in HIV-infected persons not receiving ART. In addition to the known deleterious effects of alcohol on ART adherence, these findings suggest that avoiding heavy alcohol consumption in patients not on ART may have a beneficial effect on HIV disease progression.

1 November 2001 in Journal of Orthopaedic Research
Verified
Journal Article
Closed access
BKBodo Kurz
Bodo Kurz
MJMoonsoo Jin
Moonsoo Jin
PPParth Patwari
Parth Patwari
DCDebbie M. Cheng
Debbie M. Cheng
MLMichael W. Lark
Michael W. Lark
AGAlan J. Grodzinsky
Alan J. Grodzinsky

2 March 2007 in Addiction
Verified
Journal Article
Closed access
PDF file
MLMary Jo Larson
Mary Jo Larson
MPMichael Paasche‐Orlow
Michael Paasche‐Orlow
DCDebbie M. Cheng
Debbie M. Cheng
CLChristine Lloyd‐Travaglini
Christine Lloyd‐Travaglini
RSRichard Saitz
Richard Saitz
JSJeffrey Samet
Jeffrey Samet

1 July 2008 in Journal of General Internal Medicine
Verified
Journal Article
Closed access
PDF file
AWAlexander Y. Walley
Alexander Y. Walley
JAJulie K. Alperen
Julie K. Alperen
DCDebbie M. Cheng
Debbie M. Cheng
MBMichael Botticelli
Michael Botticelli
CCCarolyn Castro-Donlan
Carolyn Castro-Donlan
DADaniel P. Alford
Daniel P. Alford

1 October 2004 in The Journal of Clinical Endocrinology & Metabolism
Verified
Journal Article
Open access
PDF file
SBSarah L. Booth
Sarah L. Booth
KBKerry E. Broe
Kerry E. Broe
JPJames W. Peterson
James W. Peterson
DCDebbie M. Cheng
Debbie M. Cheng
BDBess Dawson-Hughes
Bess Dawson-Hughes
DKDouglas P Kiel
Douglas P Kiel
Few data exist on the association between vitamin K status and bone mineral density (BMD) in men and women of varying ages. We examined cross-sectional associations between biochemical measures of vitamin K status and BMD at the hip and spine in 741 men and 863 women (mean age, 59 yr; range, 32–86 yr) who participated in the Framingham Heart Study (1996–2000). Vitamin K status was assessed by plasma phylloquinone and percentage undercarboxylated osteocalcin (%ucOC). Among the men, low plasma phylloquinone concentrations adjusted for triglycerides and elevated serum %ucOC levels were associated with low BMD at the femoral neck (P = 0.03 and 0.009, respectively). Among postmenopausal women not using estrogen replacements, low plasma phylloquinone concentrations were associated with low spine BMD (P = 0.007), with a nonsignificant trend of an elevated serum %ucOC with low spine BMD (P = 0.08). In contrast, there were no significant associations between biochemical measures of vitamin K and BMD in either premenopausal women or postmenopausal women using estrogen replacements. Clinical trials are required to isolate any putative effects of vitamin K on rates of bone loss. The target population in these trials, particularly in regard to estrogen use, may be critical, as suggested by the findings of this study.

1 August 2006 in Journal of General Internal Medicine
Verified
Journal Article
Closed access
PDF file
ALAlisa Lincoln
Alisa Lincoln
MPMichael K. Paasche-Orlow
Michael K. Paasche-Orlow
DCDebbie M. Cheng
Debbie M. Cheng
CLChristine Lloyd-Travaglini
Christine Lloyd-Travaglini
CCChristine Caruso
Christine Caruso
JSJeffrey Samet
Jeffrey Samet